Fennec Pharmaceuticals (FENC) Research & Development (2010 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Research & Development came in at $18.4 million in Q4 2025, up 366.18% YoY from $3.9 million in Q4 2024, and up 252.9% on a QoQ basis from $5.2 million in Q3 2025.
Fennec Pharmaceuticals (FENC) Research & Development (2010 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Research & Development data on file, last reported at $18.4 million in Q4 2025.
- Quarterly Research & Development rose 366.18% year-over-year to $18.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.6 million (up 101.59% YoY) and the FY2025 annual result came in at $18.6 million, up 1.03% from the prior year.
- Research & Development climbed to $18.4 million in Q4 2025, from $5.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $18.4 million in Q4 2025 to a low of $3000.0 in Q1 2024.
- A 5-year average of $2.6 million and a median of $1.2 million in 2021 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 99.72% — and 2025, when it soared 98133.33%.
- Tracing FENC's Research & Development over 5 years: stood at $523000.0 in 2021, then plunged by 77.63% to $117000.0 in 2022, then slumped by 72.65% to $32000.0 in 2023, then jumped by 12225.0% to $3.9 million in 2024, then jumped by 366.18% to $18.4 million in 2025.
- The last three Research & Development figures came in at $18.4 million (Q4 2025), $5.2 million (Q3 2025), and $107000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | 10.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.66 Mn |
| Dec 31, 2025 | 18.39 Mn |
| Sep 30, 2025 | 5.21 Mn |
| Jun 30, 2025 | 107,000.00 |
| Mar 31, 2025 | 2.95 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | 4.60 Mn |
| Jun 30, 2024 | 4.67 Mn |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 3.38 Mn |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 117,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 1.13 Mn |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | 523,000.00 |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 800,000.00 |